The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma

Blood

Volumn 114, Issue 13, 2009, Pages 2617-2618

  Chee, Cheng E ^a   Kumar, Shaji ^a   Larson, Dirk R ^a   Kyle, Robert A ^a   Dispenzieri, Angela ^a   Gertz, Morie A ^a   Colby, Colin L ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; M PROTEIN; IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL; SERUM; TREATMENT RESPONSE; URINE; BLOOD; BONE MARROW; CELL COUNT; EVALUATION; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REMISSION; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; BONE MARROW EXAMINATION; CELL COUNT; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; PROGNOSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 70350494321     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-198788     Document Type: Article

References (4)

1. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115-1123.
2. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473. (Pubitemid 44264086)
3. Lonial S, Gertz MA. Eliminating the complete response penalty from myeloma response assessment. Blood. 2008;111(6):3297-3298.
4. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22(2):231-239. (Pubitemid 351250526)